Increased Levels of Circulating Microparticles Are Associated with Increased Procoagulant Activity in Patients with Cutaneous Malignant Melanoma  by Laresche, Claire et al.
Increased Levels of Circulating Microparticles Are
Associated with Increased Procoagulant Activity in
Patients with Cutaneous Malignant Melanoma
Claire Laresche1,5, Fabien Pelletier1,2,5, Francine Garnache-Ottou2,3, Thomas Lihoreau1, Sabeha Biichle´2,3,
Guillaume Mourey2,3, Philippe Saas2,3, Philippe Humbert1,2, Estelle Seilles2,3 and Franc¸ois Aubin1,4
Microparticles (MPs) are known to be increased in various malignancies and are involved in tumor invasion,
angiogenesis, coagulation, and metastasis. We investigated the plasma levels of annexin-V MPs (AVþMPs),
platelet-derived MPs (PMPs), and endothelial-derived MPs (EMPs) in patients with melanoma (n¼ 129) and in
healthy controls (n¼ 49). A functional coagulation test STA Procoag-PPL measuring the clotting time was
performed on samples containing MPs to evaluate their procoagulant potential. The plasma levels of PMPs,
EMPs, and AVþMPs were significantly higher, and the clotting time-PPL was significantly lower in melanoma
patients than in healthy controls. The plasma levels of PMPs, EMPs, and AVþMPs were higher in stage IV than in
the other stages of melanoma, but with no significant difference. In addition, we observed an inverse correlation
between PMPs, AVþMPs, and clotting times. Our data suggest that MPs are involved in the progression of
melanoma and may be associated to melanoma-associated thrombogenesis.
Journal of Investigative Dermatology (2014) 134, 176–182; doi:10.1038/jid.2013.288; published online 12 September 2013
INTRODUCTION
Microparticles (MPs) are membrane vesicles generated from
different cellular compartments and released by any cell type
into the vascular compartment during activation or apoptosis
processes (The´ry et al., 2009). They are secreted by budding or
shedding from the plasma membrane. Membrane markers of
their originating cell are used to distinguish several circulating
MPs, including platelet-derived MPs (PMPs), which are predo-
minant in the bloodstream of healthy donors, or endothelial-
derived MPs (EMPs) (Chironi et al., 2009; Italiano et al., 2010;
Leroyer et al., 2010). Their size varies from 0.1 to 1mm
diameter. They are secreted following a stimulus yielding an
important calcium influx that modifies the activity of phos-
pholipid transmembrane carriers (that is, flippase, floppase,
and scramblase), activates calpains, and favors the burgeoning
of the plasma membrane. These phenomena lead to the
release of MPs carrying phosphatidylserine (PS) on their
surface (Martinez et al., 2004). MPs are involved in many
tumoral and inflammatory diseases such as systemic lupus
erythematosus and psoriasis (Pelletier et al., 2011). In cancer,
MPs contribute through their proteolytic properties to angio-
genesis, metastatic progression, immune escape, and throm-
bogenicity (Martı´nez et al., 2006; Lacroix et al., 2007;
Castellana et al., 2010). In cancers, MPs are not only issued
from tumor cells but they may also originate from the cells of
the host, such as platelets and endothelial cells. MPs have
been studied in a number of neoplasia, and there are few
studies in melanoma. Most studies have been performed
in vitro using murine melanoma cell lines. Lima et al (2009)
have demonstrated that the release of murine melanoma MPs
contributed to the formation of metastases. Melanoma MPs
are also involved in the production of regulatory T cells and
induce apoptosis of melanoma-specific CD8þ T lymphocytes
through the expression of Fas ligand or TRAIL (Wieckowski
et al., 2009). Moreover, thrombotic events that are a common
characteristic of all cancers may be promoted by the pro-
coagulant activity of melanoma MPs (Lima et al., 2011).
To our knowledge, no study has measured the levels of MPs
in patients with melanoma. For these reasons, we wished to
investigate the presence of MPs in melanoma and their
procoagulant properties.
RESULTS
Patients
One hundred and twenty-nine patients (74 men and 55
women) with cutaneous melanoma, including 32 stage I, 28
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stage II, 42 stage III and 27 stage IV, were investigated. Forty-
nine blood donor healthy subjects (HSs) (37 men and 12
women) were included.
PMP levels
For each stage (I, II, III, and IV), the plasma levels of PMPs
(CD31þ /CD41þ ) (2,135±1,224, 1,908±1,644, 1,860±
1,236, and 3,272±2,300 ml1, respectively) were signifi-
cantly higher (Po0.0001) in melanoma patients than in HSs
(533±570 ml1) (Table 1, Figure 1a). In addition, the
plasma levels of PMPs in patients with the American Joint
Committee on Cancer stage IV were higher than those
measured in stage I, II, and III patients, but with no
significant difference. No correlation was found between
plasma PMP levels and tumor thickness (r¼ 0.09).
EMP levels
Plasma levels of EMPs (CD31þ /CD41 phenotype) were
significantly (Po0.0001) higher in patients with stage I, III,
and IV (50±207, 14±11, and 14±8ml1, respectively) than
in HSs (7±4ml1) (Table 1, Figure1b). EMP levels did not
significantly differ between the different stages of melanoma.
No correlation was found between plasma EMP levels and
tumor thickness (r¼ 0.04).
Annexin-V MP levels
Plasma levels of annexin-V MPs (AVþMPs) were significantly
(Po0.0001) increased in patients with stage II, III, and IV
(278±373, 465±604, and 472±633ml1, respectively) as
compared with AVþMP levels measured in HSs
(76±77ml1) (Table 1, Figure1c). Plasma levels of AVþMPs
observed in stage I patients (328±855ml1) were higher than
those observed in HSs, but with no significant difference.
Although plasma levels of AVþMPs in stage IV and III patients
were higher, we did not found any significant difference
between the different stages of melanoma. No correlation
was found between plasma AVþMP levels and tumor thick-
ness (r¼0.10).
Procoagulant activity of MPs
The procoagulant activity of MPs was measured using the
functional coagulation test, STA Procoag-PPL (Table 1,
Figure 1d).
The variation of STA PPL values was associated with the
presence of MPs. As expected, samples S1–S5 demonstrated a
procoagulant activity along with high levels of PMPs. In
contrast, samples S10–S50 demonstrated normal clotting times
as measured by STA PPL and low levels of PMPs. The clotting
times were significantly longer (P¼0.04) in PMP-free plasma
(Table 2).
The clotting times were significantly (Po0.0001) lower in
stages I, II, III, and IV melanoma patients (68±17, 69±13,
64±10, and 61±14 seconds, respectively) than in
HSs (88±8 seconds). However, there was no statistical differ-
ence between the different stages of melanoma. No correlation
was found between PPL STA and tumor thickness (r¼ 0.15).
We found an inverse correlation between clotting times and
PMPs (r¼ 0.72), and AVþMPs levels (r¼ 0.21) in
patients. However, there was no correlation between clotting
times and EMP levels (r¼  0.07).
Table 1. Plasma levels of EMPs, PMPs, and AVþ MPs in patients with melanoma and in healthy control subjects
Healthy controls
(n¼ 49)
Stage I
(n¼ 32)
P-value stage
I/healthy
Stage II
(n¼ 28)
P-value stage
II/healthy
Stage III
(n¼42)
P-value stage
III/healthy
Stage IV
(n¼27)
P-value stage
IV/healthy
Age1 (years) 49±10 59±15 NS 69±17 o0.0001 60±12 o0.0001 62±15 o0.0001
Sex (male/female) 37/12 18/14 ND 13/15 ND 26/16 ND 17/10 ND
PMPs2 (CD31þ /41þ )
Mean number/s.d. 533±570 2,135±1,224 o0.0001 1,908±1,644 o0.0001 1,860±1,236 o0.0001 3,272±2,300 o0.0001
Range (92–3,421) (263–4,762) (346–8,053) (595–6,059) (393–10830)
AVþMPs2
Mean number/s.d. 76±77 328±855 NS 278±373 o0.0001 465±604 o0.0001 472±633 o0.0001
Range (6–298) (26–4,883) (47–1,397) (18–2,855) (36–2,505)
EMPs2 (CD31þ /41 )
Mean number/s.d. 7±4 50±207 o0.0001 10±7 NS 14±11 o0.0001 14±8 o0.0001
Range (1–17) (4–1,182) (2–33) (1–47) (3–38)
STA PPL3
Mean number/s.d. 88±8 68±17 o0.0001 69±13 o0.0001 64±10 o0.0001 61±14 o0.0001
Range (68–104) (43–133) (46–97) (42–86) (39–95)
Abbreviations: AV, annexin-V; EMP, endothelial-derived microparticle; MP, microparticle; ND, not determined; NS, not significant; PMP, platelet-derived
microparticles.
1Results are expressed as the mean number±s.d. of year.
2Results are expressed as the mean number±s.d. of MPs per plasma ml (range).
3Results are expressed as the mean number±s.d. of time clotting per seconds.
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DISCUSSION
Our study demonstrate that circulating PMPs are significantly
increased in melanoma at any stage compared with controls.
It is to our knowledge previously unreported. EMPs and
AVþMPs were also significantly increased in melanoma
patients at stages I, III, and IV and II, III, and IV, respectively.
However, although MP levels were much higher in stage IV
melanoma, we did not find any significant difference between
the different stages. In addition, we demonstrated that the
procoagulant activity of MPs was significantly increased at
each stage of melanoma and was correlated to the levels of
PMPs and AVþMPs.
Our data confirm the predominance of circulating plasma
PMPs in melanoma patients. The increase of PMPs has already
been found in other forms of cancer, such as gastric cancer
(Kim et al., 2003) and prostatic cancer (Helley et al., 2009).
Kim et al have shown that PMP rates were better correlated
with the severity of gastric cancer than blood dosages of
vascular endothelial growth factor, interleukin-6, and
RANTES. Kim also observed that PMP levels were correlated
with the presence of metastasis in these patients. Furthermore,
Helley et al. (2009) demonstrated that the overall survival
of patients with hormone-resistant prostate cancer varied
inversely according to the rate of PMPs.
The exact mechanisms inducing platelet activation and then
formation of PMPs in cancer are not well understood, but it
seems that there is a direct activation by the tumoral cells
releasing procoagulant molecules such as the tissue factor, as
well as an indirect activation by immune cells, which in
response to the tumoral cells release tumor necrosis factor-
alpha or interleukin-1b (Chironi et al., 2009). Circulating MPs
may have different roles in carcinogenesis. First, PMPs are
involved in angiogenesis through the secretion of prostacyclin
by monocytes and endothelial cells (Barry et al., 1999) and the
release of growth factors (vascular endothelial growth factor
and fibroblast growth factor 2) and lipids, mainly sphingosin
1-phosphate (Varon and Shai 2009). It has been demonstrated
that the angiogenic potential of PMPs is as important as the
angiogenic potential of platelets (Brill et al., 2005). PMPs also
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Figure 1. Microparticle (MP) levels and thrombogenic activity of MPs in HSs and in the different American Joint Committee on Cancer stages in melanoma
patients. (a) Platelet-derived MP (PMP) levels (CD31þ /CD41þ ), (b) endothelial-derived MP (EMP) levels (CD31þ /CD41 ), (c) annexin-V MP (AVþMP) levels,
and (d) thrombogenic activity of MPs were assessed using the functional coagulation test STA Procoag-PPL. *Indicates significant difference between the
corresponding stage of melanoma and healthy subject (HS).
Table 2. The variation of STA PPL values (expressed in s)
was associated with the presence of MPs (m 1)
PMPs (ll1) STA PPL (s)
S1 6,174 57.4
S10 697 118.4
S2 3,320 65.8
S20 405 117.7
S3 4,482 55.4
S30 525 104.1
S4 4,095 63.1
S40 604 119.9
S5 8,302 56
S50 549 120.4
Abbreviations: MP, microparticle; PMP, platelet-derived microparticle.
After an ultracentrifugation (20,000g) during 90 min, clotting times were
normal, and PMPs were low in MP-free plasma (S10–S50) compared with
initial plasmas (S1–S5) (P¼0.04 and 0.01, respectively).
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have a part in tumoral invasion, through plasminogen
activation and the production of metallopreoteases (Varon
and Shai 2009). Furthermore, they are also involved in
thrombogenicity by the presence of anionic phospholipids,
particularly PS and the procoagulant tissue factor (Varon and
Shai 2009, Suades et al., 2012).
High levels of EMPs have been already reported in cardi-
ovascular diseases (acute coronary syndromes, stroke, meta-
bolic syndrome, and hypertension), autoimmune diseases
(idiopathic thrombocytopenic purpura, antiphospholipid syn-
drome, systemic lupus erythematosus, vasculitis, and psoriasis)
(Angelot et al., 2009; Pelletier et al., 2011), but not in cancers
(Toth et al., 2008; Rank et al., 2012a). However, EMPs can be
involved in tumoral angiogenesis. Several studies have indeed
shown the involvement of EMPs at different stages of angio-
genesis (Kim et al., 2004), including matricial degradation,
recruitment and differentiation of endothelial progenitors, and
proliferation and migration of endothelial cells. Besides, EMPs
are involved in cellular survival through the induction of
cytoprotector and anti-inflammatory responses (Zernecke et al,
2009). They also demonstrate procoagulant properties through
the expression of tissue factor and phospholipids (Leroyer
et al., 2010). EMPs can also generate thrombin in vivo
and in vitro and transfer their procoagulant activity to other
cellular types, amplifying the procoagulant response (Sabatier
et al., 2011).
Hypercoagulability is well documented in all types of
cancers, and is the second leading cause of death in cancer
patients (Prandoni et al., 2005). It has been shown that MPs,
especially tumor-derived MPs, activate coagulation through
the tissue factor among other factors (Davila et al., 2008).
Our data demonstrated a statistically significant difference
between melanoma patients, irrespective of the American
Joint Committee on Cancer stage, and HSs regarding the
functional dosage of procoagulant activity of MPs. We also
observed an inverse correlation between PMP and AVþMP
levels and the clotting time measured by the functional
coagulation test STA Procoag-PPL. These data reflect the
functional procoagulant activity of circulating MPs that is
linked to the phospholipids (PS and phosphatidylethanolamin)
present at the MP surface. Tas et al. (2012) recently showed
that there was a significant difference of several coagulation
tests (prothrombin time, activated partial thromboplastin time,
prothrombin activity, D-dimer, and fibrinogen levels) between
melanoma patients and healthy subjects (HSs) and that there
was a significant difference between fibrinogen level and
survival. Suades et al. (2012) recently demonstrated that an
increased level of PMPs induced platelet deposition and
thrombus formation, even in HSs. Dvorak et al. (1983)
showed that phospholipids of MPs issued from different
tumor cell lines induced the activation of both tissue factor
and prothrombinase complex. Several previous studies have
demonstrated high levels of procoagulant MPs in patients with
neoplasia, which were correlated with the risk of thrombosis
(Rak, 2010). Thaler et al. (2012) found a correlation between
the rates of MPs carrying tissue factor and mortality in
pancreatic cancer. The presence of circulating MPs positive
for tissue factor in cancer patient has been correlated with the
progression of cancer (Leroyer et al., 2010). The origin of MPs
is still discussed. Lima et al. (2011) have shown that
melanoma tumor-derived MPs have a procoagulant activity
linked to the expression of the tissue factor on their
membrane. In our study, we only studied the phospholipidic
component of coagulation but not the tissue factor. The STA
Procoag-PPL test is a specific test that measures the specific
procoagulant activity of phospholipids but not the activity of
the tissue factor. PS expression provides a common signature
for the presence of AVþMPs. AV is considered as an useful
marker to determine general levels of MPs, although it is not
present on all MPs. However, AVþ is neither specific nor
sensitive for MPs. AV may bind with other negatively charged
phospholipids from cell fragments other than MPs, or PS may
bind to other marker than AV, for example, lactadherin. In
addition, we were not able to identify melanoma-derived MPs,
despite the use of different antibodies directed against
melanoma tumor antigens (Melan-A, MART-1, and MCSP). It
was therefore impossible to conclude on the possible
involvement of melanoma MPs in the procoagulant activity.
In our study, we cannot exclude an effect of the age of the
melanoma patients because they were significantly older than
HSs. However, it has been demonstrated that both PMPs and
EMPs did not increase with age in pre- and postmenopausal
women (Rank et al., 2012b). Furthermore, we only investi-
gated PMPs, EMP, and AVþMPs, and we cannot exclude the
presence of MPs from other cell origin, that is, inflamma-
tory, immune, or tumor cells.
In conclusion, our data demonstrate higher levels of
circulating PMPs, EMPs, and AVþMPs in melanoma patients
as compared with healthy controls in association with a
significant procoagulant activity. Further studies are required
to assess both the prognosis and the thrombogenic value of
MP levels in these patients and to determine whether these
MPs can also originate from other cell types.
MATERIALS AND METHODS
Study population
The study design was approved by the local research ethics
committee, and written informed consent was provided before
enrolment. The study adhered to the Declaration of Helsinki princi-
ples. This prospective study was conducted between April and
September 2012 in the Department of Dermatology, Besanc¸on
University Hospital, France. Patients with melanoma were included
at different clinical stages graded according to the latest American
Joint Committee on Cancer staging classification (Balch et al., 2009).
Patients with cardiovascular diseases, diabetes, chronic renal failure,
or chronic inflammatory disease were excluded. Forty-nine HSs were
enrolled in a control group (blood donors, Etablissement Franc¸ais du
Sang, Bourgogne Franche-Comte´, Besanc¸on, France). HS had no
known pathology according to the criteria imposed for blood
donation.
MP isolation from plasma
We adapted the MPs quantification method developed by the
International Society on Thrombosis and Haemostasis (Robert et al.,
2009) in 2010. Peripheral blood was drawn from healthy controls and
patients into two commercially available 5-ml citrate–theophylline–
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adenosine–dipyridamole Vacutainer tubes (Becton Dickinson, Le Pont
de Claix, France). They correspond to the second and third tubes of
collected blood.
A first centrifugation of peripheral blood was performed at 2,500g
during 15 minutes, and 1ml of platelet poor plasma was collected. A
second centrifugation of this platelet poor plasma was then performed at
2,500g during 15minutes, and 500ml of cell-free plasma was collected
and frozen at  80 1C (Pelletier et al., 2011; Lacroix et al., 2012).
MP quantification by flow cytometry
Flow cytometry was performed with a NAVIOS Cytometer (Beckman
Coulter Immunotech, Villepinte, France) (Figure 2). MPs were
identified with the following antibodies: phycoerythrin-conjugated
CD31 (clone 1F11), phycoerythrin–cyanin7-conjugated CD41 (clone
P2), and fluorescein isothiocyanate-conjugated AV (Beckman Coulter
Immunotech). To 30ml of plasma were added 5ml of AV, 5ml of
CD31, and 3ml of CD41. After a 20-minute incubation and addition
of 150ml of AV-binding buffer and 30ml of beads of counting
(Cytocount; Dako, Trappes, France), samples were performed in
duplicate and analyzed using a NAVIOS cytometer (Beckman Coulter
Immunotech, Miami, FL). MP number was calculated on the basis of
the known number of Cytocount beads added to the sample. PMPs
were identified as CD31þ /CD41þ /AVþ / events, and EMPs
were identified as CD31þ /CD41 /AVþ / . Two MP-size regions
(o0.5mm and between 0.5 and 0.9mm) were determined and
standardized daily with Megamix fluorescent beads (BioCytex,
Marseille, France) containing two types of beads with a defined size
(0.5 and 0.9mm diameter, respectively).
Validation of circulating MP quantification by flow cytometry
The Bland and Altman graphs compared the AVþMPs, MPs, and
EMPs between tubes 1 and 2. These statistical graphs confirmed the
good agreement and the reproducibility of our method of quantifica-
tion and the beads of counting standardization technique used (data
not shown).
Thrombogenic activity of MPs
Thrombogenic activity of MPs was evaluated by the functional
coagulation test STA Procoag-PPL (Diagnostica Stago, Asnie`res sur
Seine, France). It is a reproducible automated and marketed test that
measures the coagulation time associated with phospholipids. The
clotting time is dependent on the amounts of anionic phospholipid.
A first reagent (freeze-dried citrated human plasma PPL-depleted)
containing coagulation factors is added to 25ml plasma including MPs
and then centrifuged twice at 2,500 g for 15 minutes. It makes the
test dependent on procoagulant phospholipids present in the tested
sample. After incubation, a second reagent (factor X activated and
Ca2þ ) is added; it allows to trigger coagulation at the level of Xa
factor, eliminating the interaction with the previous factors. The
coagulation time was then measured. The shorter the clotting time,
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Figure 2. Analysis of circulating microparticles (MPs) using a NAVIOSTM cytometer. (a) Analysis of a sample from a healthy subject. Standardized MP-detected
areas (0.5–0.9 and o0.5mm) are represented in side scatter (SS)/forward scatter (FS) dot plot. (b) Platelet-derived MPs (PMPs) (CD31þ /CD41þ ) and endothelial-
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the more important was the procoagulant activity of phospholipids
(normal values: 72±5.6 seconds).
To confirm that the variation of STA PPL values was associated with
the presence of MPs, we carried out the following experiment. The
plasmas of five patients with melanoma were pooled in a tube. This
process was performed five times to obtain five tubes. The content
of each tube was then separated in two identical volumes and
distributed in two identical tubes for the five samples (S1–S5 and S10–
S50). In tubes (S1–S5), PMPs were counted by flow cytometry, and a
dosage of STA PPL was made. For the other tubes (S10–S50), an
ultracentrifugation was carried out at 20,000g during 90 minutes to
obtain MP-free plasma. Then, an STA PPL and a PMP dosage by flow
cytometry were performed for each plasma obtained.
Statistical analysis
The descriptive analysis of qualitative and ordinal variables includes
the number and frequency of each modality. The quantitative
variables include the mean, s.d., median, and extreme values.
Comparisons between different stages of melanoma and between
patients and healthy volunteers’ usual tests involved the nonpara-
metric Wilcoxon or Kruskal–Wallis test for semiquantitative or
quantitative non-Gaussian variables. Po0.005 was considered statis-
tically significant after applying the Bonferroni correction because of
the number of tests performed. Coefficients of correlation (spearman)
were calculated between clotting time and MP levels in patients, and
between tumor thickness and clotting time or MP levels. Statistics
were performed by the Clinical Investigation Centre of the University
Hospital of Besanc¸on using SAS software for Windows 9.3 (Stastistica
6.1, Statsoft, Maisons-Alfort, France).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This study was supported by grants from the Association Franc-Comtoise de
Recherche et De´veloppement en Dermatologie (2011). We would like to thank
Gaye Seliman, Alexandre Guichard, Fanny Angelot, Elisabeth Homassel, and
Isabelle Bruey for technical support and manuscript editing.
Author contributions
CL, FP, FA, FG-O, and ES designed the research study. CL, FP, and TL
performed experiments, analyzed data, prepared the figures and tables, and
drafted the manuscript under the supervision of FG-O, SB, GM, and ES. CL, FP,
and FA wrote the paper. CL, FP, FG-O, ES, and PH reviewed the paper.
REFERENCES
Angelot F, Seille`s E, Biichle´ S et al. (2009) Endothelial cell-derived micro-
particles induce plasmacytoid dendritic cell maturation: potential impli-
cations in inflammatory diseases. Haematologica 94:1502–12
Balch CM, Gershenwald JE, Soong S-J et al. (2009) Final version of 2009 AJCC
melanoma staging and classification. J Clin Oncol 27:6199–206
Barry OP, Kazanietz MG, Pratico` D et al. (1999) Arachidonic acid in platelet
microparticles up-regulates cyclooxygenase-2-dependent prostaglandin
formation via a protein kinase C/mitogen-activated protein kinase-depen-
dent pathway. J Biol Chem 274:7545–56
Brill A, Dashevsky O, Rivo J et al. (2005) Platelet-derived microparticles induce
angiogenesis and stimulate post-ischemic revascularization. Cardiovasc
Res 67:30–8
Castellana D, Toti F, Freyssinet J-M (2010) Membrane microvesicles: macro-
messengers in cancer disease and progression. Thromb Res 125(Suppl 2):
S84–8
Chironi GN, Boulanger CM, Simon A et al. (2009) Endothelial microparticles in
diseases. Cell Tissue Res 335:143–51
Davila M, Amirkhosravi A, Coll E et al. (2008) Tissue factor-bearing micro-
particles derived from tumor cells: impact on coagulation activation.
J Thromb Haemost 6:1517–24
Dvorak HF, Van DeWater L, Bitzer AM et al. (1983) Procoagulant activity
associated with plasma membrane vesicles shed by cultured tumor cells.
Cancer Res 43:4434–42
Helley D, Banu E, Bouziane A et al. (2009) Platelet microparticles: a
potential predictive factor of survival in hormone-refractory prostate
cancer patients treated with docetaxel-based chemotherapy. Eur Urol
56:479–84
Italiano JE Jr, Mairuhu ATA, Flaumenhaft R (2010) Clinical relevance of
microparticles from platelets and megakaryocytes. Curr Opin Hematol
17:578–84
Kim HK, Song KS, Park YS et al. (2003) Elevated levels of circulating platelet
microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer:
possible role of a metastasis predictor. Eur J Cancer 39:184–91
Kim HK, Song KS, Chung JH et al. (2004) Platelet microparticles induce
angiogenesis in vitro. Br J Haematol 124:376–84
Lacroix R, Judicone C, Poncelet P et al. (2012) Impact of pre-analytical
parameters on the measurement of circulating microparticles: towards
standardization of protocol. J Thromb Haemost 10:437–46
Lacroix R, Sabatier F, Mialhe A et al. (2007) Activation of plasminogen into
plasmin at the surface of endothelial microparticles: a mechanism that
modulates angiogenic properties of endothelial progenitor cells in vitro.
Blood 110:2432–9
Leroyer AS, Anfosso F, Lacroix R et al. (2010) Endothelial-derived micro-
particles: biological conveyors at the crossroad of inflammation, throm-
bosis and angiogenesis. Thromb Haemost 104:456–63
Lima LG, Chammas R, Monteiro RQ et al. (2009) Tumor-derived microvesicles
modulate the establishment of metastatic melanoma in a phosphatidyl-
serine-dependent manner. Cancer Lett 283:168–75
Lima LG, Oliveira AS, Campos LC et al. (2011) Malignant transformation in
melanocytes is associated with increased production of procoagulant
microvesicles. Thromb Haemost 106:712–23
Martinez MC, Kunzelmann C, Freyssinet JM et al. (2004) Remodelage
de la membrane plasmique et stimulation cellulaire. Med Sci 20:
189–95
Martı´nez MC, Larbret F, Zobairi F et al. (2006) Transfer of differentiation signal
by membrane microvesicles harboring hedgehog morphogens. Blood
108:3012–20
Pelletier F, Garnache-Ottou F, Angelot F et al. (2011) Increased levels of
circulating endothelial-derived microparticles and small-size platelet-
derived microparticles in psoriasis. J Invest Dermatol 131:1573–6
Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembo-
lism. Lancet Oncol 6:401–10
Rak J (2010) Microparticles in cancer. Semin Thromb Hemost 36:888–906
Rank A, Liebhardt S, Zwirner J et al. (2012a) Circulating microparticles in
patients with benign and malignant ovarian tumors. Anticancer Res
32:2009–14
Rank A, Nieuwland R, Roesner S et al. (2012b) Climacteric lowers plasma
levels of platelet-derived microparticles: a pilot study in pre- versus
postmenopausal women. Acta Haematol 128:53–9
Robert S, Poncelet P, Lacroix R et al. (2009) Standardization of platelet-derived
microparticle counting using calibrated beads and a Cytomics FC500
routine flow cytometer: a first step towards multicenter studies? J Thromb
Haemost 7:190–7
Sabatier F, Lacroix R, Leroyer A-S et al. (2011) Roˆle des microparticules
cellulaires a` l’interfacedes re´ponses prothrombotiques et inflammatoires.
Transfus Clin Biol 18:62–9
Suades R, Padro T, Vilahur G et al. (2012) Circulating and platelet-derived
microparticles in human blood enhance thrombosis on athrosclerotic
plaques. Thromb Haemost 108:1208–19
Tas F, Ciftci R, Kilic L et al. (2012) Clinical and pronostic signifiance of
coagulation assays in melanoma. Melanoma Res 22:368–75
C Laresche et al.
Increased Levels of Circulating Microparticles in Melanoma
www.jidonline.org 181
Thaler J, Ay C, Mackman N et al. (2012) Microparticle-associated tissue factor
activity, venous thromboembolism and mortality in pancreatic, gastric,
colorectal and brain cancer patients. J Thromb Haemost 10:1363–70
The´ry C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of
immune responses. Nat Rev Immunol 9:581–93
Toth B, Nieuwland R, Liebhardt S et al. (2008) Circulating microparticles in
breast cancer patients: a comparative analysis with established biomar-
kers. Anticancer Res 28:1107–12
Varon D, Shai E (2009) Role of platelet-derived microparticles in angiogenesis
and tumor progression. Discov Med 8:237–41
Wieckowski EU, Visus C, Szajnik M et al. (2009) Tumor-derived microvesicles
promote regulatory T cell expansion and induce apoptosis in tumor-
reactive activated CD8þ T lymphocytes. J Immunol 183:3720–30
Zernecke A, Bidzhekov K, Noels H et al. (2009) Delivery of microRNA-126 by
apoptotic bodies induces CXCL12-dependent vascular protection. Sci
Signal 2:ra81
C Laresche et al.
Increased Levels of Circulating Microparticles in Melanoma
182 Journal of Investigative Dermatology (2014), Volume 134
